Compare Abeona Therapeutics Inc (ABEO) vs iShares Gold Trust (IAU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares Gold Trust — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while iShares Gold Trust trades at $76.62. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, iShares Gold Trust nearer its low. Which is the better fit depends on your goals.
| ABEO | IAU | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $7.23 | $101.57 |
52-Week Low | $4.17 | $61.62 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
IAU trades at $78.30, up 1.02% with a bearish technical signal from moving averages while oscillators show neutrality. The stock faces resistance near $79 with support at $78. Recent news highlights strong central bank gold buying and analyst optimism for gold prices, though immediate technical indicators suggest caution.
The outlook remains mixed with bullish long-term gold fundamentals supporting IAU, but near-term technical resistance and potential Fed policy shifts pose risks. Investors should weigh strong institutional gold demand against current overbought short-term signals and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares Gold Trust
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →
